NCT06095414 is a clinical trial of MRI in Breast Cancer, sponsored by Korea University Ansan Hospital.

Who is sponsoring NCT06095414?

NCT06095414 is sponsored by Korea University Ansan Hospital.

What drugs are being tested in NCT06095414?

Interventions in NCT06095414: MRI.

What condition does NCT06095414 study?

NCT06095414 studies Breast Cancer.

Is NCT06095414 still recruiting?

NCT06095414 is currently completed. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT06095414

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Radiomics Study for Breast Cancer

Completed Last updated 23 October 2023

What this trial tests

trial testing MRI in Breast Cancer in 121 participants. Completed in 30 August 2023.

Timeline

1 June 2020

Primary endpoint
30 April 2022

30 August 2023

Quick facts

Lead sponsor	Korea University Ansan Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	121
Start date	1 June 2020
Primary completion	30 April 2022
Estimated completion	30 August 2023
Sites	1 location across South Korea

Drugs / interventions tested

MRI — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Korea University Ansan Hospital

Who can join

Adults 20 to 90, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this prospective study is to develop MRI-based models representing tumor microenvironment in participants with invasive breast cancer. The main purpose of this study is to analyze the association of diffusion-, T2-, and dynamic contrast-enhanced T1-weighted images of 3T MRI before treatment with the immunohistochemical reactivity of tumor microenvironment including the extracellular matrix and immune cells of core-needle biopsy specimens For this purpose, investigators extract 16145 radiomic features from the intratumoral and peritumoral regions on MRI of participants with invasive breast cancer before treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Optimized prediction of breast cancer tumor microenvironment using MRI-based intratumoral and peritumoral radiomics: a prospective study.
Kim ES, Ham S, Seo BK, Lee JY, et al · · 2025 · PMID 41278298 · DOI 10.3389/fonc.2025.1654508

Verify or expand the search:

Other trials of MRI

Trials testing the same drug.

NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Korea University Ansan Hospital trials

Trials by the same sponsor.

NCT07452666 — FISTULA-RFA Trial: Radiofrequency Ablation for Perianal Fistula · NA · not yet recruiting
NCT05978154 — Thigh Muscle Mass and Muscle Wasting in Patients in the Emergency Department · unknown
NCT05817019 — Postoperative Sugammadex After COVID-19 · Phase 4 · unknown
NCT05438121 — STabilization of Atheroma by Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB) · recruiting
NCT06104189 — Prospective Ultrafast MRI Radiomics for Breast Cancer · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06095414 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Korea University Ansan Hospital
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06095414.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing